The FDA has expanded the use of nivolumab approval for the treatment of Stage IIB/C melanoma in adolescents.

Published Date: 19 Oct 2023

The FDA-approved nivolumab (Opdivo; Bristol Meyers Squibb Company) is now available for use as an adjuvant treatment for patients with fully resected Stage IIB/C melanoma who are 12 years of age and older.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot